Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

Glofitamab is in clinical development for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL) and primary mediastinal large B-cell lymphoma (PMBCL). HGBCL and PMBCL are subtypes of DLBCL which is a type of blood cancer that develops when white blood cells, called lymphocytes, grow out of control. Relapsed cancer refers to cancer that initially responded to treatment but then returned. Refractory cancer refers to cancer that did not respond to treatment. The prognosis for patients with relapsed or refractory DLBCL remains poor, so there is a need to develop additional treatment options.
Glofitamab is developed as an intravenous infusion to target and eliminate certain white blood cells allowing treatment of B-cell cancers. If licensed, glofitamab would offer an alternative treatment option for adult patients with relapsed or refractory DLBCL, HGBCL and PMBCL.